This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
IOVA Q4 Earnings Beat, Stock Down on Looming Economic Uncertainty
by Zacks Equity Research
Iovance reports better-than-expected fourth-quarter results. The stock plunges on warnings of adverse macroeconomic factors harming its business.
PCRXNegative Net Change ARGXPositive Net Change IOVANo Net Change ETNBNegative Net Change
biotechs cell-therapy earnings medical
PBYI Stock Rises as Q4 Earnings & Sales Outpace Estimates
by Zacks Equity Research
Puma Biotechnology beats on fourth-quarter 2024 earnings and sales. The company issues a fresh financial guidance for 2025.
FOLDNegative Net Change PCRXNegative Net Change PBYIPositive Net Change IMCRPositive Net Change
biotechs
Xenon Q4 Loss Narrower Than Expected, Pipeline Development in Focus
by Zacks Equity Research
XENE reports a narrower-than-expected fourth-quarter 2024 loss. Its development programs for azetukalner in epilepsy and MDD are progressing well.
BMRNNegative Net Change GILDNegative Net Change NBIXNegative Net Change XENEPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Viatris Q4 Earnings and Revenues Miss Estimates, Stock Plunges
by Zacks Equity Research
VTRS Q4 earnings and sales miss estimates. The guidance for 2025 looks disappointing due to the financial impact of the Indore facility warning letter and import alert. Stock down.
BMRNNegative Net Change GILDNegative Net Change FOLDNegative Net Change VTRSPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Novavax Q4 Loss Narrower Than Expected, Sales Beat Estimates
by Zacks Equity Research
NVAX reports encouraging fourth-quarter results. It completes the sale of its Czech Republic manufacturing unit to Novo Nordisk for $200 million.
SNYPositive Net Change NVOPositive Net Change NVAXPositive Net Change
biotechs medical pharmaceuticals vaccines
Acadia's Q4 Earnings Miss, Nuplazid & Daybue Drive Revenue Growth
by Zacks Equity Research
ACAD reports mixed fourth-quarter results as earnings missed estimates while revenues beat the same, driven by year-over-year growth in Nuplazid and Daybue sales.
BMRNNegative Net Change GILDNegative Net Change FOLDNegative Net Change ACADNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
MIRM's Q4 Loss Wider Than Expected, Revenues Beat Estimates
by Zacks Equity Research
Mirum's fourth-quarter 2024 earnings miss estimates while revenues beat the same.
RIGLPositive Net Change PCRXNegative Net Change ARGXPositive Net Change MIRMNegative Net Change
biotechs earnings
CPRX Q4 Earnings Beat, Firdapse Sales Boost Revenues, Stock Up
by Zacks Equity Research
Catalyst stock gains on strong fourth-quarter results, beating earnings and revenue estimates, primarily driven by Firdapse sales.
BMRNNegative Net Change GILDNegative Net Change FOLDNegative Net Change CPRXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Sarepta Q4 Earnings Lag Estimates, Revenues Gain on Gene Therapy Sales
by Zacks Equity Research
SRPT reports mixed fourth-quarter 2024 results. It closes the multi-billion-dollar deal with Arrowhead and adds four new clinical programs to its pipeline.
RHHBYPositive Net Change SRPTNegative Net Change ARWRNegative Net Change
biotechs earnings gene-editing gene-therapy medical pharmaceuticals
Madrigal Q4 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up
by Zacks Equity Research
MDGL stock is rising as it reports better-than-expected fourth-quarter results, beating earnings and revenue estimates, driven by strong Rezdiffra sales.
BMRNNegative Net Change BEAMPositive Net Change FOLDNegative Net Change MDGLNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Beam Therapeutics' Q4 Earnings & Revenues Beat Estimates
by Zacks Equity Research
BEAM incurs a narrower-than-expected loss in the fourth quarter. The company remains focused on pipeline development.
BEAMPositive Net Change PCRXNegative Net Change ARGXPositive Net Change
biotechs earnings
Biotech Stock Roundup: BLUE Down on Update, News From GILD, TRDA
by Zacks Equity Research
BLUE and GILD are in the spotlight this week on key updates.
BMRNNegative Net Change GILDNegative Net Change TRDANegative Net Change
biotechnology biotechs medical pharmaceuticals
Should You Add RIGL Stock to Your Portfolio Pre-Q4 Earnings?
by Ekta Bagri
Rigel Pharmaceuticals has put up a strong performance in 2024 and should maintain momentum in 2025. Irrespective of how the company fares in Q4, we recommend investors to add the stock to their portfolio.
RDYNegative Net Change RIGLPositive Net Change
biotechnology biotechs earnings-preview medical pharmaceuticals
SANA Gears Up to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Sana Biotechnology's Q4 2024 earnings call, investors can expect updates regarding the developmental programs for its clinical-stage candidates.
PCRXNegative Net Change ARGXPositive Net Change MIRMNegative Net Change SANAPositive Net Change
biotechnology biotechs earnings medical oncology-screening pharmaceuticals
CSTL Gears Up to Report Q4 Earnings: Here's What You Should Know
by Zacks Equity Research
Castle Biosciences' fourth-quarter 2024 earnings are likely to have gained from higher test volume growth of its dermatologic and non-dermatologic tests.
PCRXNegative Net Change MIRMNegative Net Change CSTLPositive Net Change
biotechs
ITCI Q4 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales
by Zacks Equity Research
Intra-Cellular reports mixed fourth-quarter 2024 results, wherein earnings miss estimates but revenues beat the same driven by strong Caplyta sales.
JNJPositive Net Change BMRNNegative Net Change FOLDNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
What's in Store for These 5 Biotech Stocks This Earnings Season?
by Ahan Chakraborty
Let's look at five biotech and drug companies, VTRS, PRGO, NVAX, NTLA and IOVA, slated to release their fourth-quarter 2024 results on Feb. 27, 2025.
PRGONegative Net Change NVAXPositive Net Change NTLANegative Net Change IOVANo Net Change VTRSPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals vaccines
RIGL Stock Surges 41.4% in a Year: Time to Buy or Sell?
by Ekta Bagri
Rigel Pharmaceuticals has put up a strong performance in 2024 and should maintain momentum in 2025. We believe there is more room for growth.
RDYNegative Net Change RIGLPositive Net Change
biotechnology biotechs medical pharmaceuticals
Should You Buy VKTX Stock Amid Renewed M&A Speculations?
by Sundeep Ganoria
Given the optimism around its obesity candidate, we believe investors should stay invested in Viking Therapeutics, regardless of buyout speculations.
PFENegative Net Change NVOPositive Net Change LLYPositive Net Change VKTXNegative Net Change
biotechs medical pharmaceuticals
5 High Earnings Yield Value Stocks to Buy Amid Market Volatility
by Rimmi Singhi
Volatility looms with sticky inflation, a slowing economy and Trump's trade policies. Buy high-earnings-yield stocks like NUS, HRMY, PAHC, DAN and NRG.
NRGNegative Net Change DANNegative Net Change NUSNegative Net Change PAHCNegative Net Change HRMYNegative Net Change
auto-tires-trucks biotechs consumer-staples energy medical retail
What's in the Cards for Viatris Stock This Q4 Earnings?
by Zacks Equity Research
VTRS' Q4 results are likely to gain from new product launches in all major geographies.
PCRXNegative Net Change VKTXNegative Net Change MIRMNegative Net Change VTRSPositive Net Change
biotechnology biotechs medical pharmaceuticals
Prothena Q4 Earnings Miss Estimates, Pipeline Progress in Focus
by Zacks Equity Research
PRTA posts a wider-than-expected fourth-quarter loss. However, it reports encouraging pipeline progress for the quarter.
RHHBYPositive Net Change BMYNegative Net Change NVOPositive Net Change PRTAPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
4 Seniors & Aging Demographics Stocks to Watch Right Now
by Urmimala Biswas
ABBV, AMGN, SYK and DXCM are well-poised to benefit from the evolving new opportunities in Seniors & Aging Demographics within healthcare.
ABTNegative Net Change AMGNPositive Net Change MDTNegative Net Change SYKNegative Net Change DXCMNo Net Change ABBVPositive Net Change
artificial-intelligence biotechnology biotechs medical medical-devices oncology-screening pharmaceuticals
SpringWorks' Q4 Loss Wider Than Expected, Revenues Beat Estimates
by Zacks Equity Research
SWTX reports mixed fourth-quarter 2024 results. Its newly approved desmoid tumor drug, Ogsiveo, witnesses a strong launch.
PCRXNegative Net Change ARGXPositive Net Change
biotechs earnings
Cassava Gears Up to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On SAVA's fourth-quarter 2024 earnings call, investors can expect updates regarding the company's pipeline developmental plans amid recent setbacks.
PCRXNegative Net Change ARGXPositive Net Change SAVAPositive Net Change MIRMNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals